No official medical body has published a definitive list of “nine prescription drugs that cause dementia,” but the lists circulating online draw from real research linking several common drug classes to increased dementia risk. Most of these drugs share a property called anticholinergic activity, meaning they block a brain chemical involved in memory and learning. The evidence is strongest for certain antihistamines, bladder medications, benzodiazepines, and tricyclic antidepressants, with weaker or more mixed signals for sleep aids, opioids, anti-seizure drugs, proton pump inhibitors, and corticosteroids. The relationship between these medications and cognitive decline is more complicated than a viral list suggests, and understanding which drugs carry genuine risk, how much exposure matters, and what you can actually do about it is worth more than memorizing nine names.
Why So Many of These Drugs Overlap
The thread connecting most medications on these lists is their anticholinergic effect. Acetylcholine is a chemical messenger your brain relies on for attention, learning, and forming new memories. Drugs that block it can produce foggy thinking, confusion, and memory trouble even after a single dose. A large case-control study using English medical records found that people prescribed drugs with the strongest anticholinergic activity had roughly 11% higher odds of developing dementia compared with people who were not prescribed those drugs, and the risk climbed with increasing anticholinergic burden over time.1BMJ. Anticholinergic drugs and risk of dementia: case-control study That 11% may sound modest, but it represents the average across all strong anticholinergics. Individual drug classes can carry steeper risk depending on dose and how long you take them.
It is also worth stating clearly: “linked to dementia risk” is not the same as “causes dementia.” Most of this research is observational, meaning it tracks groups of people who happen to be taking these drugs and compares their dementia rates with non-users. People prescribed these medications often have underlying conditions (chronic pain, depression, anxiety, insomnia) that themselves raise dementia risk. Researchers try to control for those factors statistically, but residual confounding is always possible. The signal is strong enough that clinicians take it seriously, but it is not the same kind of evidence as, say, knowing that smoking causes lung cancer.
First-Generation Antihistamines
Diphenhydramine (the active ingredient in many over-the-counter sleep aids and allergy pills) is one of the most commonly named drugs in these lists. It is a potent anticholinergic, and while you can buy it without a prescription, doctors also prescribe it. A prospective study that followed older adults for an average of about seven years found that those with the highest cumulative anticholinergic exposure, including first-generation antihistamines, had about 54% higher dementia risk compared with non-users.2JAMA Internal Medicine. Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study A separate study focused specifically on people with allergic rhinitis found a dose-dependent pattern: those who used first-generation antihistamines at the highest cumulative doses had about 51% greater dementia risk compared with non-users.3The Journal of Allergy and Clinical Immunology: In Practice. Cumulative Dose Effects of H1 Antihistamine Use on the Risk of Dementia in Patients With Allergic Rhinitis
Second-generation antihistamines like cetirizine and loratadine have far less anticholinergic activity and do not appear to carry the same risk. If you take antihistamines regularly for allergies, these newer options are the ones most physicians would steer you toward, and not only for cognitive reasons: they also cause less drowsiness.
Bladder Medications
Overactive bladder drugs, particularly oxybutynin, are among the strongest anticholinergics prescribed to older adults. A nested case-control study found that oxybutynin use was associated with about a 31% increase in dementia odds at moderate cumulative doses.4PubMed Central. Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study A large Danish study went further, finding that ever-use of anticholinergic bladder drugs was associated with a 44% higher dementia rate, with the risk climbing to 68% higher among people who used the most.5PubMed Central. Bladder drugs and risk of dementia: Danish nationwide active comparator study In that study, tolterodine, solifenacin, trospium, and fesoterodine all showed elevated risk, not just oxybutynin.
This class matters because overactive bladder is extremely common in older adults, and the drugs are frequently prescribed for years. Newer alternatives like mirabegron work through a different mechanism entirely and do not have anticholinergic activity, which is why geriatric specialists increasingly favor them.
Benzodiazepines
Drugs like diazepam (Valium), lorazepam (Ativan), and alprazolam (Xanax) are prescribed for anxiety, insomnia, and seizures. A case-control study found that any use of benzodiazepines was associated with about 51% higher odds of Alzheimer’s disease, and the risk was dose-dependent: people who used them for more than six months had roughly 84% higher odds.6BMJ. Benzodiazepine use and risk of Alzheimer’s disease: case-control study Long-acting benzodiazepines (like diazepam) carried somewhat higher risk than short-acting ones (like lorazepam). A meta-analysis confirmed that long-term use was associated with about 21% higher dementia risk compared with short-term use.7PubMed Central. Risk of Dementia in Long-Term Benzodiazepine Users: Evidence from a Meta-Analysis of Observational Studies
The caveat here is the same one that haunts all observational drug-dementia research: people prescribed benzodiazepines often have anxiety or insomnia, both of which may themselves be early symptoms or risk factors for dementia. Still, the dose-response pattern (more use, more risk) is hard to explain away entirely with confounding, and most clinical guidelines now recommend against long-term benzodiazepine use in older adults for this and other safety reasons.
Sleep Medications Including Z-Drugs
Zolpidem (Ambien), zaleplon, and eszopiclone are sometimes called Z-drugs. They are not benzodiazepines, but they act on similar brain receptors. A population-based study found that zolpidem use was associated with about 33% higher dementia odds after controlling for other medications and health conditions.8PubMed Central. An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: a population-based case-control study A broader study from the Atherosclerosis Risk in Communities cohort found that late-life sleep medication use overall (including benzodiazepines and Z-drugs together) was associated with 48% greater dementia risk over about six and a half years of follow-up.9PubMed Central. Associations of Late-Life Sleep Medication Use With Incident Dementia in the Atherosclerosis Risk in Communities Study
The evidence is not entirely one-directional, though. One study of middle-aged and older patients with chronic insomnia found that Z-drug use did not correlate with worse global cognitive function.10PubMed Central. Association Between Z Drugs Use and Risk of Cognitive Impairment in Middle-Aged and Older Patients With Chronic Insomnia The inconsistency might reflect differences in study populations, duration of use, or the fact that untreated insomnia itself damages cognition. The safest interpretation is that chronic use of these drugs in older adults adds risk, while occasional short-term use is less concerning.
Tricyclic Antidepressants
Older antidepressants like amitriptyline and nortriptyline have strong anticholinergic effects. They appear on virtually every “drugs linked to dementia” list. A study in the UK Biobank found that tricyclic antidepressant use was associated with about 36% higher dementia risk compared with people who had never used antidepressants.11PubMed Central. Antidepressant use in relation to dementia risk, cognitive decline, and brain atrophy Selective serotonin reuptake inhibitors (SSRIs) like sertraline and citalopram, which have minimal anticholinergic activity, showed a weaker and statistically insignificant association in the same study. Neither class showed a dose-response relationship or acceleration of brain shrinkage, which complicates the causal interpretation.
The chicken-and-egg problem is especially acute with antidepressants: depression itself is a well-established risk factor for dementia, and people who need antidepressants by definition have depression. A study specifically looking at paroxetine, an SSRI with unusually high anticholinergic properties, found it did not increase dementia risk compared with other SSRIs in nursing home residents.12PubMed Central. Anticholinergic medication use and dementia: latest evidence and clinical implications This does not mean antidepressants are safe for the brain, but it does mean the signal is muddier than it is for, say, bladder drugs.
Opioid Painkillers
Chronic opioid use for pain management has been linked to dementia risk in several large studies. A study of patients with chronic pain found that opioid users had roughly 86% higher dementia risk than non-users in a multivariate analysis, though the adjusted incidence ratio was more modest at about 13% higher.13PubMed. Long-Term Opioid Use and Dementia Risk in Patients With Chronic Pain A large Danish population study showed a clear dose-response pattern: cumulative exposure beyond about 90 standardized daily doses was associated with progressively higher dementia rates, ranging from roughly 29% higher at moderate doses to 59% higher at the highest doses in people aged 60 to 69.14JAMA Network Open. Opioids and Dementia in the Danish Population Short-term opioid use showed no consistent link.
Opioids are not anticholinergic, so the mechanism here is likely different. Chronic opioid use affects brain regions involved in memory and reward, and chronic pain itself contributes to cognitive decline. The Danish data also found that the association weakened in the oldest age groups, suggesting the relationship may partly reflect the conditions being treated rather than the drugs alone.
Anti-Seizure Medications
Drugs like valproate and carbamazepine show up in some versions of these lists. A meta-analysis of ten observational studies found that anti-seizure medication use was associated with about 9% higher dementia risk overall, but this association disappeared when studies adjusted for the conditions the drugs were being used to treat.15PubMed Central. Anti-seizure medication exposure and the risk of dementia: A meta-analysis of observational studies In other words, epilepsy and bipolar disorder themselves may account for much of the observed risk. Among individual drugs, valproate and carbamazepine showed positive associations, while newer anti-seizure drugs did not.
People with bipolar disorder who took anti-seizure medications had about 43% higher dementia risk in the same analysis, but again, bipolar disorder carries its own cognitive risks. This is one of the weakest links in the “nine drugs” lists, and the most responsible reading of the evidence is that the disease being treated matters more than the medication itself for most patients.
Proton Pump Inhibitors
Omeprazole (Prilosec), lansoprazole (Prevacid), and their relatives are among the most widely used drugs in the world, prescribed for acid reflux and ulcers. Several observational studies have reported associations between long-term PPI use and dementia.16PubMed Central. Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks However, the evidence is genuinely inconsistent. A Mendelian randomization study, which uses genetic variation to test for causal relationships rather than relying on prescription records, found no strong causal link between PPI use and dementia overall after statistical corrections.17Scientific Reports. Association between proton pump inhibitors and dementia risk: a Mendelian randomization study
A separate Mendelian randomization study found that lansoprazole specifically might increase risk for Alzheimer’s disease, while omeprazole might increase risk for frontotemporal dementia but potentially decrease risk for vascular dementia.18PubMed. Causal relationship between proton pump inhibitors and dementia risk: evidence from a Mendelian randomization study These results are preliminary and the confidence intervals are wide enough to be cautious. The honest summary is that PPIs probably should not be on a list of drugs that “cause” dementia in the same way anticholinergics are. The association exists in some data, but it does not hold up consistently when researchers try to move beyond correlation.
Corticosteroids
Prednisone and other glucocorticoids are prescribed for a wide range of inflammatory conditions. They are known to impair memory during use. A study of patients on chronic prednisone found that they performed worse on explicit memory tests compared with controls, and elderly patients appeared more susceptible to these effects even with shorter treatment courses.19PubMed. The effect on memory of chronic prednisone treatment in patients with systemic disease However, this memory impairment does not always meet the clinical threshold for dementia, and the distinction between drug-induced cognitive impairment and true dementia is an important one. Conditions that cause cognitive symptoms during treatment do not necessarily produce permanent dementia; some are partially or fully reversible once the drug is stopped.20PubMed Central. Reversible dementias
Corticosteroid-induced memory problems are among the most likely to improve after discontinuation, which makes them somewhat different from the cumulative-exposure pattern seen with anticholinergics or benzodiazepines.
Drugs That Don’t Deserve Their Spot on the List
Statins get mentioned in some versions of these lists, partly because the FDA once added a warning about potential memory effects. A large target trial emulation study found that statin users did have a 46% spike in dementia diagnoses during the first year of treatment, but after that initial year, there was no difference in dementia rates between statin users and non-users.21PubMed Central. Statin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020: A Target Trial Emulation Study The early spike likely reflects detection bias: starting a statin puts you in regular contact with a doctor, and cognitive symptoms that were already developing get noticed and diagnosed sooner. The drug itself does not appear to increase long-term dementia risk, and some cardiovascular researchers believe that by protecting blood vessels, statins might even help preserve cognition over decades. If you see statins on a “drugs that cause dementia” list, treat it skeptically.
Similarly, certain blood pressure medications that cross into the brain may actually lower Alzheimer’s risk. A study of over 69,000 people treated with beta-blockers for hypertension found that highly brain-permeable beta-blockers were associated with a small reduction in Alzheimer’s diagnoses compared with less permeable ones.22PubMed Central. Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer’s disease in hypertension Treating high blood pressure is one of the most evidence-backed things you can do to protect your brain as you age, so stopping blood pressure medication out of dementia fear would be counterproductive.
Why Dose and Duration Are the Real Story
Across nearly every drug class linked to dementia, the pattern is the same: short-term or low-dose use shows little or no association, while years of cumulative exposure raise risk substantially. The prospective cohort study on anticholinergics found no meaningful increase at low cumulative doses, but roughly 54% higher risk among the heaviest users over a decade.2JAMA Internal Medicine. Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study The benzodiazepine data showed a similar staircase: no significant increase for less than three months of use, then climbing steadily beyond that.6BMJ. Benzodiazepine use and risk of Alzheimer’s disease: case-control study Danish opioid data showed the same pattern, with exposure below about 90 days showing no consistent link.14JAMA Network Open. Opioids and Dementia in the Danish Population
This means a single course of prednisone for a flare-up, a few weeks of a benzodiazepine during a crisis, or occasional use of diphenhydramine for a bad allergy day is not what the research is flagging. The concern is with chronic, daily, years-long use, which is unfortunately how many of these drugs end up being taken, especially in older adults who started a medication for a short-term problem and never stopped.
Polypharmacy and the Stacking Effect
Many older adults take five or more medications simultaneously, and the cognitive impact of these drugs can stack. Research from the DO-HEALTH trial found that polypharmacy was associated with about 28–33% higher odds of mild cognitive impairment over three years, though this association weakened when researchers accounted for the underlying health conditions driving all those prescriptions.23Journal of the American Medical Directors Association. Association of Polypharmacy With Mild Cognitive Impairment in Community-Dwelling Older Adults: A 3-Year Prospective Analysis of the DO-HEALTH Trial Even so, someone taking a bladder drug, a sleep aid, and a tricyclic antidepressant simultaneously is stacking anticholinergic load in a way that likely exceeds any individual drug’s risk. A review of deprescribing practices noted that up to 56% of people with dementia are taking at least one potentially inappropriate medication.24PubMed Central. Deprescribing for People with Dementia: A Roadmap
If you are taking several of the medications discussed here, the conversation to have with your doctor is not just about any one drug in isolation but about the total anticholinergic and sedative load across your entire medication list. Pharmacists trained in geriatric care can calculate this burden using standardized scoring tools, and the result sometimes surprises both patients and prescribers.
Genetic Vulnerability
Not everyone’s brain responds to these drugs the same way. The ApoE4 gene variant, already the strongest genetic risk factor for Alzheimer’s, appears to amplify drug-induced cognitive harm. In animal research, rats carrying the ApoE4 gene showed greater impairment in visual and spatial memory after drug exposure compared with rats carrying the more common ApoE3 variant, along with reduced formation of new brain cells in the hippocampus.25Scientific Reports. Influence of ApoE genotype on doxorubicin-induced cognitive impairment in juvenile rats This was studied with a chemotherapy drug rather than the medications discussed above, so direct translation to anticholinergics or benzodiazepines requires caution. But the principle that genetic background shapes vulnerability to drug-induced cognitive damage is well-recognized in clinical practice. If you know you carry ApoE4 (increasingly available through consumer genetic testing), it is a reason to be especially cautious about long-term use of any medication flagged in this area.
How Over-the-Counter Access Complicates the Picture
Several of the strongest anticholinergics are available without a prescription. Diphenhydramine is sold as a sleep aid and allergy pill. Doxylamine, another first-generation antihistamine, is in many nighttime cold formulas. These are the same drugs that carry the most consistent dementia signals in research, yet because they are available over the counter, they often go untracked. Your doctor may not know you have been taking diphenhydramine nightly for years because it never shows up on your prescription record. Studies that rely on prescription databases for exposure data systematically undercount anticholinergic use, which means the true association between these drugs and dementia may be stronger than the numbers suggest. If you use any over-the-counter sleep or allergy medication regularly, mention it at your next appointment so it can be factored into your overall medication assessment.